Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024Business Wire • 02/26/24
History Says the Nasdaq Will Keep Soaring in 2024 -- and Wall Street Thinks This High-Yield Dividend Stock Could Jump Nearly 20%The Motley Fool • 02/24/24
Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration AgreementBusiness Wire • 02/20/24
RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New PublicationPRNewsWire • 02/20/24
CYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CymaBay Therapeutics, Inc. - CBAYBusiness Wire • 02/16/24
CymaBay Stock Rockets After Gilead Sciences Unveils $4.3 Billion AcquisitionInvestors Business Daily • 02/12/24
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay TherapeuticsBusiness Wire • 02/12/24